Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2026-03-27
DOI
https://doi.org/10.1016/j.esmogo.2026.100316
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies

Kenichi Yoshimura
ESMO Gastrointestinal Oncology
HER2/EGFR in Cancer Research
article

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies

Kenichi Yoshimura
article en

Abstract

No abstract available for this paper.
ESMO Gastrointestinal OncologyVol. 12
Nagoya City University (JP)
Zero hunger
Openalex Percentile: Top 5%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies — Kenichi Yoshimura · ESMO Gastrointestinal Oncology (2026) | TGRS Research Map | TGRS